Stock Groups

EU fails to confirm if women, young adults at higher clot risk from AstraZeneca shot By Reuters


© Reuters. FILEPHOTO: This illustration photo taken on March 24, 2021 shows a virus labeled “AstraZeneca Coronavirus Disease (COVID-19), vaccine”. REUTERS/Dado Ruvic/Illustration

(Reuters) – Europe’s drugs regulator said on Friday it could not confirm if women and young adults were at a higher risk of rare blood clots with low platelets following vaccination with AstraZeneca (NASDAQ:)’s COVID-19 vaccine after it studied available data.

Limitations in the way the data was collected meant that the European Medicines Agency could not identify any specific risk factor that made the condition, thrombosis with thrombocytopenia syndrome (TTS), more likely, it said

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are rather provided by market makers. Therefore prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.